The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
 
Cesar Serrano
Honoraria - Bayer
Consulting or Advisory Role - Deciphera
Research Funding - Bayer; Deciphera
Travel, Accommodations, Expenses - Pfizer
 
Alessandro Leal
No Relationships to Disclose
 
Jillian Phallen
No Relationships to Disclose
 
Adrian Marino-Enriquez
No Relationships to Disclose
 
Yanan Kuang
No Relationships to Disclose
 
Olivia Triplett
No Relationships to Disclose
 
Jeffrey A. Morgan
No Relationships to Disclose
 
Constance Barysauskas
No Relationships to Disclose
 
Andrew J. Wagner
Consulting or Advisory Role - Five Prime Therapeutics; Lilly; Loxo
Research Funding - AADi (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst)
 
George D. Demetri
Leadership - Blueprint Medicines
Stock and Other Ownership Interests - Bessor Pharma; Blueprint Medicines; Caris Life Sciences; Champions Oncology; G1 Therapeutics; N-of-One
Consulting or Advisory Role - Adaptimmune; Bayer; Blueprint Medicines; Caris Life Sciences; Daiichi Sankyo; Eisai; EMD Serono; G1 Therapeutics; Genocea Biosciences; Janssen Oncology; Kolltan Pharmaceuticals; Kyocera; Lilly; Nektar; Novartis; Pfizer; PharmaMar; Polaris; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Janssen Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Patent on use of imatinib for GIST, receive minor royalty payment from Dana-Farber after license between Dana-Farber and Novartis
 
Victor E. Velculescu
Leadership - Personal Genome Diagnostics
Stock and Other Ownership Interests - Ignyta; Personal Genome Diagnostics
Consulting or Advisory Role - Ignyta; Janssen Diagnostics; Personal Genome Diagnostics; Quintiles
Patents, Royalties, Other Intellectual Property - Receive royalties for discoveries our group has made at Johns Hopkins that have been licensed by Genzyme.; Receive royalties for discoveries our group has made at Johns Hopkins that have been licensed by Myriad.; Receive royalties for discoveries our group has made at Johns Hopkins that have been licensed by Personal Genome Diagnostics.; Receive royalties for discoveries our group has made at Johns Hopkins that have been licensed by Qiagen.; Receive royalties for discoveries our group has made at Johns Hopkins that have been licensed by Roche.
 
Cloud Paweletz
Honoraria - Bio-Rad
Consulting or Advisory Role - DropWorks
 
Jonathan A. Fletcher
Consulting or Advisory Role - ARIAD; Bayer; Lilly
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - Novartis - Imatinib
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie (I)
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; deciphera
Research Funding - ARIAD (Inst); Bayer (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate